novo retatrutide Retatrutide, a triple agonist, delivered 30.3% weight loss at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% of body weight) → 🚨 Novo Acquires Retatrutide Competitor

Novo and Lilly have each invested billions expanding peptide production facilities in the U.S

Pharmacokinetic parameters were evaluated using the WinNonlin software (version 5.3) according to a non-atrioventricular model

Please see the updated Small Group Submission Checklist with refreshed materials in the Small Group Sales Resource Center

Research Evidence Comparison# Retatrutide Research# Phase 1 : First-in-human study established safety and pharmacokinetics Phase 2 (n=338) : Published in NEJM (2023), demonstrated dose-dependent weight loss up to 24.2% at 48 weeks with 12 mg dose

While one is a master antioxidant that lightens skin tone by reducing melanin, the other is a structural protein that acts as the glue keeping your skin firm and youthful